GlassScriptPhysician profile
David Alexandre Chetrit
NPI 1285155010
$8,170.50
in general payments reported to CMS, 2019-2025
33 companies · $2,259 in 2025
The $2,259 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $739 · 2023: $2,887 · 2024: $2,286 · 2025: $2,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,431.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,229.49 | 2022-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,786.13 | 2022-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $1,094.26 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $794.81 | 2022-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $683.00 | 2022-2025 | |
| Novo Nordisk INC | $210.77 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $156.26 | 2024-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.21 | 2023-2025 | Ofev, Jardiance |
| Radius Health, INC. | $115.84 | 2022-2025 | Tymlos |
| Pfizer INC. | $102.03 | 2023-2025 | |
| Averitas Pharma INC. | $77.99 | 2023 | Qutenza |
| Calliditas Therapeutics US INC. | $70.44 | 2023-2024 | Tarpeyo |
| Horizon Therapeutics Plc | $66.71 | 2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $63.41 | 2023-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $58.50 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $55.94 | 2022-2024 | Benlysta |
| Kyowa Kirin, INC. | $52.62 | 2024 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $44.49 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $42.79 | 2022-2024 | |
| Genentech USA, INC. | $40.35 | 2024-2025 | Actemra |
| Boston Scientific Corporation | $36.30 | 2023-2024 | Watchman Flx, Watchman Access System |
| Teva Pharmaceuticals USA, INC. | $36.26 | 2023-2024 | Truxima |
| Alexion Pharmaceuticals, INC. | $32.03 | 2023-2024 | Strensiq |
| Organon LLC | $27.75 | 2025 | Renflexis, Hadlima |
| Grt US Holding, INC. | $26.50 | 2022 | |
| Medicomp INC | $23.20 | 2023 | Telepatch Cardiac Monitor |
| Xeris Pharmaceuticals, INC. | $19.94 | 2023 | Gvoke Hypopen |
| Electromed, INC. | $18.03 | 2024 | Smartvest |
| Janssen Scientific Affairs, LLC | $17.16 | 2023 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $14.70 | 2023 | Trintellix |
| Halozyme INC | $14.67 | 2023 | |
| Insulet Corporation | $13.98 | 2023 | Omnipod |
| Sanofi-Aventis U.S. LLC | $13.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chetrit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.